Deregulation of miR-126 expression in colorectal cancer pathogenesis and its clinical significance.

Exp Cell Res

Cancer Molecular Pathology, School of Medicine, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia; Pathology Queensland and Gold Coast University Hospital, Gold Coast, Queensland, Australia. Electronic address:

Published: December 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In this study, we investigated the expression profiles and clinicopathological significance of miR-126 in large cohort of patients with colorectal cancers as well the cellular repercussions of miR-126 in colon cancer cells along with its targets in-vitro. Down regulation of miR-126 expression was associated with histological subtypes, peri-neural tumour infiltration, microsatellite instability and pathological staging of colorectal cancers (p<0.05). Low miR-126 expression was also associated with poorer survival in patients with colorectal cancer. Analysis of matched tissues from the same patient revealed that approximately 70% of the tested patients had similar levels of expression of miR-126 in primary cancer and cancer metastases in both lymph node and distant metastases. In addition, induced overexpression of miR-126 showed reduced cell proliferation, increased apoptosis and decreased accumulation of cells in the G0-G1 phase of the colon cancer cells. Furthermore, SW480(+miR-126) cells showed reduced BCL-2 and increased P53 protein expression. To conclude, deregulation of miR-126 in colorectal cancer at the tissue and cellular levels as well as its correlation with various clinicopathological parameters confirm the cancer suppressive role of miR-126 in colorectal cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2015.10.004DOI Listing

Publication Analysis

Top Keywords

mir-126 expression
8
colorectal cancers
8
deregulation mir-126
4
expression colorectal
4
colorectal cancer
4
cancer pathogenesis
4
pathogenesis clinical
4
clinical significance
4
significance study
4
study investigated
4

Similar Publications

Background: At present, existing risk scores together with traditional biomarkers such as troponin and brain natriuretic peptide (BNP) are still unable to accurately predict cancer therapy-related cardiac dysfunction (CTRCD). MicroRNAs (miRNAs) have emerged as promising biomarkers for improved identification of high-risk patients; however, limited studies have been performed in patients with HER2-positive breast cancer.

Objectives: To investigate the predictive potential of six serum-derived circulating miRNAs for CTRCD occurrence in patients with early-stage HER2-positive breast cancer receiving trastuzumab (TTZ).

View Article and Find Full Text PDF

Introduction: Ischemic heart disease (IHD) remains a major global health burden, highlighting the urgent need for early, non-invasive diagnostic biomarkers. MicroRNAs (miRNAs), small non-coding RNA molecules that regulate gene expression, have emerged as promising candidates due to their stability in circulation and involvement in cardiovascular processes. This systematic review aimed to evaluate the potential of specific miRNAs as early diagnostic biomarkers in IHD.

View Article and Find Full Text PDF

NUTM2A-AS1 is an emerging long noncoding RNA (lncRNA) that has garnered significant attention due to its multifaceted roles in cancer biology. As a member of the ceRNA network, NUTM2A-AS1 modulates gene expression by sequestering microRNAs, thereby influencing key oncogenic pathways. This review aims to provide a comprehensive overview of the current understanding of NUTM2A-AS1 in the development, progression, and metastasis of various cancers, including gastric cancer, hepatocellular carcinoma, neuroblastoma, colorectal cancer, glioma, lung adenocarcinoma, prostate cancer, and renal cell carcinoma.

View Article and Find Full Text PDF

Background: Ursodeoxycholic acid (UDCA) is the first-line therapeutic agent for primary biliary cholangitis (PBC). However, a subset of patients exhibit a suboptimal response to UDCA, and reliable predictive biomarkers remain elusive. Studies have implicated plasma microRNAs (miRNAs) in the pathophysiological progression of PBC, with certain miRNAs demonstrating potential as diagnostic and disease progression biomarkers.

View Article and Find Full Text PDF

MiR-126-3p and MiR-195-5p as Novel Therapeutic Attenuators of Liver Fibrosis by Targeting the IRS1/PI3K Signalling Pathway.

Liver Int

October 2025

Key Laboratory of Target Discovery and Protein Drug Development in Major Diseases, School of Bioscience and Technology, Chengdu Medical College, Chengdu, Sichuan, People's Republic of China.

Background & Aims: Hepatic fibrosis is a progressive response to chronic liver injury. A key event in the development of hepatic fibrosis is the activation of hepatic stellate cells (HSCs); emerging research indicates that microRNAs play crucial roles in regulating HSCs activation. However, the specific roles of miR-126-3p (miR-126) and miR-195-5p (miR-195) in liver fibrosis remain inadequately understood.

View Article and Find Full Text PDF